11/03/19 Demonstration of Keratin 17 Biomarker for Urothelial Carcinoma Detection

Bladder carcinoma is a common urological cancer with high morbidity, mortality, and recurrence rates requiring frequent, invasive diagnostic procedures...more(1)more(2)

4 views

Recent Posts

See All

07/03/20 KDx Diagnostics Announces CE Marking for Innovative Non-invasive URO17™ Bladder Cancer Test

KDx Diagnostics, Inc., announced today that it has received Conformité Européene (CE) Marking for its innovative and proprietary urine-based test (the URO17™ test) for bladder cancer...more

9Write a comment

01/08/20 KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17™ Bla

6Write a comment

10/08/19 A Better Future

A new biomarker allows effective, noninvasive screening of patients at risk of the disease. Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine profes

1Write a comment